- GlobeNewswire•8 days ago
Current Cash is projected to Fund the Company through Three Clinical Trial Read-Outs and into 2019. CARMIEL, Israel, March 16, 2017-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused ...
- GlobeNewswire•15 days ago
Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017
CARMIEL, Israel, March 09, 2017-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its ...
- TheStreet.com•last month
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
PLX.TA : Summary for PROTALIX BIOTHERAP COM STK USD0 - Yahoo Finance
Protalix BioTherapeutics, Inc. (PLX.TA)
Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
Add to watchlist
|Bid||421.30 x 128000|
|Ask||423.00 x 209400|
|Day's Range||414.00 - 436.00|
|52 Week Range||1.11 - 436.00|
|PE Ratio (TTM)||-1,452.76|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|